Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 3;2013(12):CD006044.
doi: 10.1002/14651858.CD006044.pub4.

Lamotrigine for chronic neuropathic pain and fibromyalgia in adults

Philip J Wiffen  1 , Sheena Derry, R Andrew Moore
Affiliations
Review

Lamotrigine for chronic neuropathic pain and fibromyalgia in adults

Philip J Wiffen et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an update of the original Cochrane review entitled Lamotrigine for acute and chronic pain published in Issue 2, 2007, and updated in Issue 2, 2011. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This updated review adds no new additional studies looking at evidence for lamotrigine as an effective treatment for chronic neuropathic pain or fibromyalgia. The update uses higher standards of evidence than previously.

Objectives: To assess the analgesic efficacy of lamotrigine in the treatment of chronic neuropathic pain and fibromyalgia, and to evaluate adverse effects reported in the studies.

Search methods: We identified randomised controlled trials (RCTs) of lamotrigine for chronic neuropathic pain and fibromyalgia (including cancer pain) from MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL). We ran searches for the original review in 2006, in 2011 for the first update, and subsequent searches in August 2013 for this update. We sought additional studies from the reference lists of the retrieved papers. The original review and first update included acute pain, but no acute pain studies were identified.

Selection criteria: RCTs investigating the use of lamotrigine (any dose, by any route, and for any study duration) for the treatment of chronic neuropathic pain or fibromyalgia. Assessment of pain intensity or pain relief, or both, using validated scales. Participants were adults aged 18 and over. We included only full journal publication articles.

Data collection and analysis: Two review authors independently extracted efficacy and adverse event data, and examined issues of study quality. We performed analysis using three tiers of evidence. The first tier used data where studies reported the outcome of at least 50% pain reduction from baseline, lasted at least eight weeks, had a parallel group design, included 200 or more participants in the comparison, and reported an intention-to-treat analysis. First-tier studies did not use last observation carried forward (LOCF) or other imputational methods for dropouts. The second tier used data that failed to meet this standard and second-tier results were therefore subject to potential bias.

Main results: Twelve included studies in 11 publications (1511 participants), all with chronic neuropathic pain: central post-stroke pain (1), chemotherapy-induced neuropathic pain (1), diabetic neuropathy (4), HIV-related neuropathy (2), mixed neuropathic pain (2), spinal cord injury-related pain (1), and trigeminal neuralgia (1). We did not identify any additional studies. Participants were aged between 26 and 77 years. Study duration was two weeks in one study and at least six weeks in the remainder; eight were of eight-week duration or longer.No study provided first-tier evidence for an efficacy outcome. There was no convincing evidence that lamotrigine is effective in treating neuropathic pain and fibromyalgia at doses of 200 mg to 400 mg daily. Almost 10% of participants taking lamotrigine reported a skin rash.

Authors' conclusions: Large, high-quality, long-duration studies reporting clinically useful levels of pain relief for individual participants provided no convincing evidence that lamotrigine is effective in treating neuropathic pain and fibromyalgia at doses of about 200 to 400 mg daily. Given the availability of more effective treatments including antiepileptics and antidepressant medicines, lamotrigine does not have a significant place in therapy based on the available evidence. The adverse effect profile of lamotrigine is also of concern.

PubMed Disclaimer

Conflict of interest statement

SD and PW have received research support from charities, government and industry sources at various times, but none relate to this review.

RAM has consulted for various pharmaceutical companies and received lecture fees from pharmaceutical companies related to analgesics and other healthcare interventions, including (in the past five years) AstraZeneca, Eli Lilly, Flynn Pharma, Furtura Medical, Grünenthal, GSK, Horizon Pharma, Lundbeck, Menarini, MSD, Pfizer, Reckitt Benckiser, Sanofi Aventis, Urgo, Astellas, and Vifor Pharma.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Forest plot of comparison: 1 Painful diabetic neuropathy, outcome: 1.1 50% pain relief.
4
4
Forest plot of comparison: 2 All conditions: lamotrigine versus placebo, outcome: 2.2 Rash.
1.1
1.1. Analysis
Comparison 1 Painful diabetic neuropathy: lamotrigine versus placebo, Outcome 1 50% pain relief.
2.1
2.1. Analysis
Comparison 2 All conditions: lamotrigine versus placebo, Outcome 1 At least one adverse event.
2.2
2.2. Analysis
Comparison 2 All conditions: lamotrigine versus placebo, Outcome 2 Rash.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Eisenberg 2001 {published data only}
    1. Eisenberg E, Lurie Y, Breker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57(3):505‐9. - PubMed
    1. Lurie Y, Brecker C, Daoud D, Ishay A, Eisenberg E. Lamotrigine in the treatment of painful diabetic neuropathy: a randomized placebo controlled study. Progress in Pain Research and Management 2000;16:857‐62.
Finnerup 2002a {published data only}
    1. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002;96(3):375‐83. [DOI: 10.1016/S0304-3959(01)00484-5] - DOI - PubMed
Jose 2007 {published data only}
    1. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double‐blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Medicine 2007; Vol. 24:377‐83. [DOI: 10.1111/j.1464-5491.2007.02093.x] - DOI - PubMed
McCleane 1999 {published data only}
    1. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double‐blind, placebo controlled trial. Pain 1999;83(1):105‐7. [DOI: 10.1016/S0304-3959(99)00095-0] - DOI - PubMed
Rao 2008 {published data only}
    1. Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, et al. Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy: a phase 3 randomized, double‐blind, placebo‐controlled trial, N01C3. Cancer 2008; Vol. 112:2802‐8. [DOI: 10.1002/cncr.23482] - DOI - PubMed
Silver 2007 {published data only}
    1. NPP30010. A multicenter, randomized, double‐blind, placebo‐controlled, parallel group study to evaluate the safety and efficacy of lamotrigine in subjects with neuropathic pain and inadequate pain relief with gabapentin, tricyclic antidepressants or non‐narcotic analgesics. www.gsk‐clinicalstudyregister.com/ (Accessed 7 August 2013) 2005.
    1. Silver M, Blum D, Grainger J, Hammer AE, Quessy S. Double‐blind, placebo‐controlled trial of lamotrigine in combination with other medications for neuropathic pain. Journal of Pain and Symptom Management 2007; Vol. 34:446‐54. [DOI: 10.1016/j.jpainsymman.2006.12.015] - DOI - PubMed
Simpson 2000 {published data only}
    1. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel‐Frommer K. A placebo‐controlled trial of lamotrigine for painful HIV‐associated neuropathy. Neurology 2000;54(11):2115‐9. - PubMed
Simpson 2003 {published data only}
    1. Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, et al. Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV‐associated painful sensory neuropathies: a placebo‐controlled trial. Neurology 2003;60(9):1508‐14. - PubMed
Vestergaard 2001 {published data only}
    1. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001;56(2):184‐90. - PubMed
Vinik 2007a {published data only}
    1. Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double‐blind, placebo‐controlled studies. Pain 2007; Vol. 128:169‐79. [DOI: 10.1016/j.pain.2006.09.040] - DOI - PubMed
Vinik 2007b {published data only}
    1. Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double‐blind, placebo‐controlled studies. Pain 2007;128:169‐79. [DOI: 10.1016/j.pain.2006.09.040] - DOI - PubMed
Zakrzewska 1997 {published data only}
    1. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double‐blind placebo controlled crossover trial. Pain 1997;73(2):223‐30. [DOI: 10.1016/S0304-3959(97)00104-8] - DOI - PubMed

References to studies excluded from this review

Bonicalzi 1997 {published data only}
    1. Bonicalzi V, Canavero S, Cerutti F, Piazza M, Clemente M, Chio A. Lamotrigine reduces total postoperative analgesic requirement: a randomized double‐blind, placebo‐controlled pilot study. Surgery 1997;122(3):567‐70. [DOI: 10.1016/S0039-6060(97)90129-X] - DOI - PubMed
Breuer 2007 {published data only}
    1. Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK. A randomized, double‐blind, placebo‐controlled, two‐period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clinical Therapeutics 2007; Vol. 29:2022‐30. [DOI: 10.1016/j.clinthera.2007.09.023] - DOI - PubMed
Carrieri 1998 {published data only}
    1. Carrieri PB, Provitera VV, Lavorgna L, Bruno R. Response of thalamic pain syndrome to lamotrigine. European Journal of Neurology 1998;5(6):625‐6. - PubMed
Devulder 2000 {published data only}
    1. Devulder J, Laat M. Lamotrigine in the treatment of chronic refractory neuropathic pain. Journal of Pain Symptom Management 2000;19(5):398‐403. [DOI: 10.1016/S0885-3924(00)00131-7] - DOI - PubMed
Di Vadi 1998 {published data only}
    1. Vadi PP, Hamann W. The use of lamotrigine in neuropathic pain. Anaesthesia 1998;53(8):808‐9. [DOI: 10.1046/j.1365-2044.1998.00564.x] - DOI - PubMed
Eisenberg 1998 {published data only}
    1. Eisenberg E, Alon N, Ishay A, Daoud D, Yarnitsky D. Lamotrigine in the treatment of painful diabetic neuropathy. European Journal of Neurology 1998;5(2):167‐73. [DOI: 10.1046/j.1468-1331.1998.520167.x] - DOI - PubMed
Eisenberg 2003 {published data only}
    1. Eisenberg E, Damunni G, Hoffer E, Baum Y, Krivoy N. Lamotrigine for intractable sciatica: correlation between dose, plasma concentration and analgesia. European Journal of Pain 2003;7(6):485‐91. [DOI: 10.1016/S1090-3801(03)00020-X] - DOI - PubMed
Eisenberg 2005 {published data only}
    1. Eisenberg E, Shifrin A, Krivoy N. Lamotrigine for neuropathic pain. Expert Review of Neurotherapeutics 2005; Vol. 5:729‐35. [DOI: 10.1586/14737175.5.6.729] - DOI - PubMed
Lunardi 1997 {published data only}
    1. Lunardi G, Leandri M, Albano C, Cultrera S, Fracassi M, Rubino V, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997;48(6):1714‐7. - PubMed
Petersen 2003 {published data only}
    1. Petersen KL, Maloney A, Hoke F, Dahl JB, Rowbotham MC. A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization. Journal of Pain 2003;4(7):400‐6. - PubMed
Sandner‐Kiesling 2002 {published data only}
    1. Sandner‐Kiesling A, Rumpold Seitlinger G, Dorn C, Koch H, Schwarz G. Lamotrigine monotherapy for control of neuralgia after nerve section. Acta Anaesthesiologica Scandinavica 2002;46(10):1261‐4. [DOI: 10.1034/j.1399-6576.2002.461014.x] - DOI - PubMed
Shaikh 2011 {published data only}
    1. Shaikh S, Yaacob HB, Abd Rahman RB. Lamotrigine for trigeminal neuralgia: efficacy and safety in comparison with carbamazepine. Journal of the Chinese Medical Association 2011;74(6):243‐9. [DOI: 10.1016/j.jcma.2011.04.002] - DOI - PubMed

Additional references

Apkarian 2011
    1. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2011;152(3 Suppl):S49‐64. [DOI: 10.1016/j.pain.2010.11.010] - DOI - PMC - PubMed
Attal 2010
    1. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113‐e88. [DOI: 10.1111/j.1468-1331.2010.02999.x] - DOI - PubMed
AUREF 2012
    1. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 1 August 2013).
Birse 2012
    1. Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009485.pub2] - DOI - PMC - PubMed
Bouhassira 2008
    1. Bouhassira D, Lantéri‐Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380‐7. [DOI: 10.1016/j.pain.2007.08.013] - DOI - PubMed
Cook 1995
    1. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310 1995;310(6977):452‐4. - PMC - PubMed
Corrigan 2012
    1. Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009486.pub2] - DOI - PMC - PubMed
Derry 2012
    1. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111] - DOI - PMC - PubMed
Derry 2013
    1. Derry S, Sven‐Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3] - DOI - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
Dworkin 2010
    1. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic Proceedings 2010;85(3 Suppl):S3‐14. [DOI: 10.4065/mcp.2009.0649] - DOI - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. [DOI: 10.1093/ije/31.1.140] - DOI - PubMed
Finnerup 2002b
    1. Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opinions in Pharmacotherapy 2002;3(10):1411‐20. [DOI: 10.1517/14656566.3.10.1411] - DOI - PubMed
Gill 2011
    1. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009183.pub2] - DOI - PMC - PubMed
Gustorff 2008
    1. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. [DOI: 10.1111/j.1399-6576.2007.01486.x] - DOI - PubMed
Hall 2008
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26] - DOI - PMC - PubMed
Hearn 2012
    1. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009318.pub2] - DOI - PMC - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Hirsch 2006
    1. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, et al. Predictors of lamotrigine‐associated rash. Epilepsia 2006;47(2):318‐22. [DOI: 10.1111/j.1528-1167.2006.00423.x] - DOI - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [DOI: 10.1016/0197-2456(95)00134-4] - DOI - PubMed
Jensen 2002
    1. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. European Journal of Pain 2002;6(Suppl A):61‐8. [DOI: 10.1053/eujp.2001.0324] - DOI - PubMed
Jensen 2011
    1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204‐5. [DOI: 10.1016/j.pain.2011.06.017] - DOI - PubMed
Katusic 1991
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945‐1984. Neuroepidemiology 1991;10(5‐6):276‐81. - PubMed
Khaliq 2013
    1. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia [withdrawn]. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD004846.pub2] - DOI - PMC - PubMed
Khan 1996
    1. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine 1996;156(6):661‐6. - PubMed
Koopman 2009
    1. Koopman JS, Dieleman JP, Huygen FJ, Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] - DOI - PubMed
Koroschetz 2011
    1. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain－differences and similarities: a comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55] - DOI - PMC - PubMed
L'Abbe 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107(2):224‐33. - PubMed
Lunn 2009
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2] - DOI - PubMed
McCleane 2000
    1. McCleane GJ. Lamotrigine in the management of neuropathic pain. The Clinical Journal of Pain 2000;16:321‐6. - PubMed
McNally 2006
    1. McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self‐reported fibromyalgia in Canada. Chronic Diseases in Canada 2006;27(1):9‐16. - PubMed
McQuay 1998
    1. McQuay H, Moore R. An evidence‐based resource for pain relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐263048‐2]
McQuay 2007
    1. McQuay HJ, Smith LA, Moore RA. Chronic Pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007.
Moisset 2007
    1. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimaging 2007;37(Suppl 1):S80‐8. - PubMed
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2009a
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed
Moore 2009b
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2009;Online:April 12. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2010a
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain‐‐establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2010b
    1. Moore RA, Straube S, Derry S, McQuay HJ. Topical review: chronic low back pain analgesic studies ‐ a methodological minefield. Pain 2010;149(3):431‐4. [DOI: 10.1016/j.pain.2010.02.032] - DOI - PubMed
Moore 2010c
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] - DOI - PubMed
Moore 2010d
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2011a
    1. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] - DOI - PMC - PubMed
Moore 2011b
    1. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982‐9. [DOI: ] - PubMed
Moore 2011c
    1. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427‐32. [DOI: 10.1097/EJA.0b013e328343c569] - DOI - PubMed
Moore 2012a
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Moore 2012b
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
Moore 2013a
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2013;March 6:Epub ahead of print. [DOI: 10.1111/papr.12050] - DOI - PubMed
Moore 2013b
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs－'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148] - DOI - PubMed
NICE 2013
    1. NICE clinical guideline 173. Neuropathic pain – pharmacological management. www.nice.org.uk/guidance/CG173 (accessed 26 November 2013) 2013:1‐138.
O'Brien 2010
    1. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6‐15. [DOI: 10.1111/j.1526-4637.2009.00685.x] - DOI - PubMed
Phillips 2010
    1. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV‐associated sensory neuropathy: a systematic review and meta‐analysis of randomised controlled trials. PLoS One 2010;5(12):e14433. [DOI: 10.1371/journal.pone.0014433] - DOI - PMC - PubMed
Rappaport 1994
    1. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain 1994;56(2):127‐38. [DOI: 10.1016/0304-3959(94)90086-8] - DOI - PubMed
RevMan 2012 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Soni 2013
    1. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: a community‐based study. Arthritis & Rheumatism 2013;April 1:Epub ahead of print. [DOI: 10.1002/art.37962] - DOI - PMC - PubMed
SPC 2013
    1. Summary of product characteristics for Lamictal. Section 4.8. www.medicines.org.uk Accessed 8 August 2013.
Straube 2008
    1. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266‐75. [DOI: 10.1111/j.1365-2125.2008.03200.x] - DOI - PMC - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia‐‐responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29] - DOI - PMC - PubMed
Torrance 2006
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey. Journal of Pain 2006;7(4):281‐9. [DOI: 10.1016/j.jpain.2005.11.008] - DOI - PubMed
Tracey 2011
    1. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nature Reviews Neurology 2011;7(3):173‐81. [doi: 10.1038/nrneurol.2011.4] - PubMed
Treede 2008
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630‐5. - PubMed
Wiffen 2011b
    1. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD005451.pub2] - DOI - PMC - PubMed
Wiffen 2013a
    1. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010567] - DOI - PMC - PubMed
Wiffen 2013b
    1. Wiffen PJ, Derry S, Lunn MPT, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD008314.pub3] - DOI - PMC - PubMed
Wolfe 1990
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33(2):160‐72. - PubMed
Wolfe 2010
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62(5):600‐10. [DOI: 10.1002/acr.20140] - DOI - PubMed
Zheng 2010
    1. Zheng C, Yang K, Liu Q, Wang MY, Shen J, Valles SA, et al. The anticonvulsive drug lamotrigine blocks neuronal{alpha}4{beta}2‐nicotinic acetylcholine receptors. The Journal of Pharmacology and Experimental Therapeutics 2010;Aug 5:Epub ahead of print. [DOI: 10.1124/jpet.110.171108] - DOI - PubMed

References to other published versions of this review

Wiffen 2007
    1. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006044.pub2] - DOI - PubMed
Wiffen 2011a
    1. Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006044.pub3] - DOI - PMC - PubMed